Dr. Tslil Braun went looking for cells that had pressed their own self-destruct button and lived to tell about it. She found them. Then she found the catch: when those survivors divide, their descendants come back 7 times harder to kill than the tissue they grew out of.
That second half is why an oncologist should care about a study done in fruit flies. Programmed cell death, apoptosis, is supposed to be a one-way door. A cell commits, the molecular machinery runs, the cell is taken apart and cleared. It is how a body shapes a developing limb and disposes of cells that have turned dangerous, and it is the function a great deal of cancer medicine leans on: radiation and many chemotherapies work by shoving malignant cells through that door and slamming it. So the question Braun and her colleagues at Israel’s Weizmann Institute of Science put on the table was the one nobody had chased down: what becomes of the cells that get most of the way through and walk back out.
“We set out to identify cells that push the self-destruct button but survive anyway,” Braun said. They found them.
The team dosed fruit fly larvae with ionizing radiation, rerunning a regeneration puzzle first documented in the 1970s, and watched what came back. Most of the irradiated cells died as expected. A subpopulation did not. These the researchers named DARE cells, for death-apoptosis-resistant epithelial cells: they fired the opening move of apoptosis and then stalled it before the executioner enzymes could finish the job. Within 48 hours, according to the paper in Nature Communications, DARE cells and a second death-resistant population had multiplied and replenished nearly half of the damaged tissue.
The mechanism is where it gets interesting for anyone who treats cancer. The initiator caspase Dronc, the enzyme that normally starts the death cascade, switches on in these cells but never lands the killing blow, because an unconventional myosin motor called Myo1D binds Dronc and holds the process at that first step, so the executioner caspases that would take the cell apart never fire. The alarm rings; the detonation never comes. It sits in the same neighborhood as anastasis, the documented recovery of a cell from the brink of programmed death, though what the paper describes is stricter still: a phenomenon catalogued about a decade ago in which cells claw back after the executioners have already fired, whereas these cells never let them fire at all.
That was where the coverage stopped, and on its own it is a lovely piece of biology. The press led with the healing: tissue that rebuilds itself, cells that survive lethal damage and get back to work. The darker story is what those healed cells hand down to the generation after them.
When the researchers irradiated the survivors a second time, the offspring of the DARE cells came back 7 times more resistant to cell death than cells in the original tissue. The trick is heritable, and it compounds. And Myo1D, the motor doing the holding, is no stranger to the cancer literature: overactivation of that same protein had already been linked to tumor growth, which is what turns an elegant regeneration finding into an uncomfortable one. A cell that can survive its own scheduled execution, teach its children to survive it better, and shrug off the next round of damage is not just a model of healing. It is a working sketch of how a tumor comes back.
Prof. Eli Arama, who led the work, did not oversell it, but he did not soften what it points at either. “Many cancers originate in epithelial cells that have lost normal growth control,” he said, “and many traditional cancer treatments aim to cause them to self-destruct through apoptosis. Our findings pave the way for understanding why such treatments sometimes fail and how they could be improved.” His team said it plainer in its own summary: cancer cells may exploit this same survival mechanism, returning as tumors that are more aggressive and harder to treat. That is the recurrence every oncologist dreads, the cancer that walks off the therapy that beat it the first time, and here is a candidate mechanism for it caught mid-act.
The honest limit is that this happened in Drosophila, and folding that limit into the story sharpens it rather than blunts it. This is not a healing breakthrough and it is not a therapy; there is no drug, no company, no approval package to pick apart. What it is instead is a target. Flies are a serious, time-tested tool precisely because conserved mechanisms found in them have a habit of holding up in humans, and a caspase held in check by a myosin motor is now a specific, testable reason some cancers survive the treatments built to kill them. A warning sign with an address on it is worth more than another triumphant press release, and rarer, too. The same researchers who found the cells that cheat death are the ones telling you to keep an eye on them.
Sources
- ScienceDaily – “Scientists discover cells that cheat death and rebuild damaged tissue” (Weizmann Institute release, Sept. 2026)
- Nature Communications – Braun, Arama, et al., “Apoptosis-resistant cells drive compensatory proliferation via cell-autonomous and non-autonomous functions of the initiator caspase Dronc” (2025), DOI 10.1038/s41467-025-65996-2
- Vanguard – “Cells that cheat death: new clue to why some cancers return” (Sept. 2026)
- PMC – Sun & Montell, “Anastasis: recovery from the brink of cell death” (review, background on the phenomenon)